TNFSF10 and cancer: Our current findings of the enhancement of DR5 activation-induced apoptosis by b-AP15 warrant further investigation of b-AP15 in combination with TRAIL or DR5 agonistic antibody as an effective cancer therapeutic regimen in vivo and in the clinic, and underscore the clinical translational significance of this approach.